B

Biograph

Premium preventive health diagnostics and longevity

Business Development Lead

Full-Time
$110k - $150k/yr+ Equity
Senior
Bachelor's
New York, NY, USA
HybridTypically 3–5 days per week in the Manhattan office; occasional travel for pitches, conferences, and partner events.
Sales & Account ManagementAccount Executive

About the job

Requirements
  • At least 5 years of experience in high-growth B2B business development, enterprise sales, or strategic partnerships.
  • A bachelor's degree in Business, Healthcare Administration, Communications, or a related field, or equivalent practical experience.
  • A proven track record of navigating complex corporate hierarchies and closing high-dollar deals with C-suite decision-makers.
  • Presentation, storytelling, and negotiation skills, including the ability to turn complex clinical data into a compelling business case.
  • Comfort working in the dynamic, fast-paced environment of a healthcare technology startup.
  • Proficiency with modern customer relationship management tools such as HubSpot and Salesforce, and outbound prospecting platforms.
  • Analytical skills to build financial business cases and return-on-investment models for prospective clients.
  • Ability to travel occasionally for high-stakes pitches, conferences, and partner events.
Responsibilities
  • Identify, target, and close enterprise-level B2B deals with Fortune 500 companies, technology startups, and major organizations seeking to improve executive health and employee wellness.
  • Lead the business development lifecycle from cold outreach and initial pitch through complex contract negotiations and handoff to operations.
  • Explain the scientific and economic value of the diagnostic platform to C-suite executives, human resources leaders, and benefits stakeholders.
  • Develop impact analyses and advise key decision-makers throughout the account lifecycle to demonstrate platform value and establish long-term corporate relationships.
  • Build relationships with brokers, advisors, and benefits consultants to supplement the direct-to-employer pipeline.
  • Coordinate with operations and marketing to align market demand with operational capacity and support onboarding of corporate partners.
  • Build and maintain pipeline data systems to track deal progress, forecast growth, and refine sales strategies based on real-world feedback.
Desired Qualifications
  • Experience in health technology, corporate wellness, or executive health.
  • An existing network of C-suite executives, institutional partners, and enterprise human resources leaders that can be leveraged immediately.
  • A track record of closing a major corporate pilot or high-impact partnership within the first 90 days in a new role.
  • Past B2B deals originated and closed that resulted in measurable annual recurring revenue growth or multi-year institutional alignment.
  • Experience building repeatable, scalable outbound playbooks from scratch in early-stage environments.
  • A strong interest in longevity, preventative medicine, and the future of healthcare.

About the company

B

Biograph

View
Website

Biograph runs premium preventive health and diagnostics clinics focused on longevity and early disease detection. It uses a two-tier membership—Core at $7,500 and Black at $15,000—to deliver a same-day, comprehensive assessment with over 1,000 data points using whole-body MRI, CT, genetic testing, DEXA, and VO2 max. After testing, a Biograph physician reviews results in a one-on-one consultation and helps create an actionable plan with dietitians and exercise physiologists, all in a luxurious, retreat-like setting that complements traditional healthcare. The company focuses on five health pillars and highlights that more than 15% of members uncover urgent or life-altering conditions, underscoring its emphasis on early detection and personalized risk management.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Mateo, California

Founded

2018

Get referred to Biograph

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Biograph launched its women’s health program on August 19, 2026.
  • Biograph expanded to New York City in 2026, widening access beyond San Francisco.
  • Biograph raised $559 million in January 2025, funding aggressive clinic expansion.

What critics are saying

  • Function Health, Prenuvo, and Fountain Life pressure Biograph on price and reach.
  • Whole-body MRI creates incidental findings, follow-up costs, and anxiety among healthy members.
  • Biograph sells expensive concierge prevention to wealthy patients; recessionary demand gaps can freeze growth.

What makes Biograph unique

  • Peter Attia and John Hering anchor Biograph’s longevity brand and trust.
  • Biograph compresses 30-plus assessments into one day across New York and San Francisco.
  • Core and Black memberships pair diagnostics with physician-led follow-through, dietitians, and exercise physiologists.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Company Equity
  • Unlimited Paid Time Off
  • Paid Maternity / Paternity Leave

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

0%
Vero Bioscience
Sep 14th, 2026
Solving the "what next" Problem in health diagnostics.

Solving the "what next" Problem in health diagnostics. Vero co-founder Paul Coletta joins Scott Nelson Live to explain why a diagnosis without a next step isn't a product - and how his own kidney's silent aging led him to found Vero. Vero Bioscience Team September 14, 2026 Key takeaways. * Paul Coletta's own OrganAge test flagged an accelerated kidney despite normal standard labs - a follow-up ultrasound found a benign renal cyst his usual panel had missed. * Vero's core critique of health diagnostics: a number without a next step isn't a product. Vero Compass closes that loop by pairing a finding with an intervention, then remeasuring. * OrganAge reads ~11,000 of the body's ~25,000 gene-coding proteins from one blood draw, trained on a 45,000-person UK Biobank cohort followed for 17 years. * The technology is already published in Nature as a validated surrogate biomarker; Vero is now pursuing separate clinical validation through IRB studies with partners like Biograph. * Vero is targeting a fall 2027 direct-to-consumer launch, with several thousand people already on its waitlist. Vero co-founder and CEO Paul Coletta sat down with Scott Nelson Live to talk about a gap he sees across most health-diagnostics companies: they hand people a number and leave them stranded, with no path to act on it. A kidney that standard labs missed. Coletta's own path to Vero started with an early version of the test he'd go on to commercialize. It flagged accelerated aging in his kidney - even though his traditional bloodwork looked completely normal. A follow-up ultrasound found a renal cyst. Benign, but a real sign of aging his standard panel had missed entirely. Closing the loop, not just flagging risk. That gap is what Coletta calls the "what next" problem, and it's the premise behind Vero Compass: pairing an organ-level finding with a targeted, evidence-informed intervention, then remeasuring to confirm whether it actually worked. "It's what's going to be sort of game-changing about what we're bringing to market." - Paul Coletta Early access Discover your OrganAge(TM). Join its waitlist to get priority access to OrganAge(TM) and Vero Compass(TM) as they become more widely available. From Stanford research to clinical validation. OrganAge reads roughly 11,000 of the body's ~25,000 gene-coding proteins from a single blood draw, trained on a 45,000-person UK Biobank cohort followed for 17 years. The underlying science is already published in Nature as a validated surrogate biomarker - a distinct bar, Coletta notes, from full clinical validation, which Vero is now pursuing through IRB studies with clinical partners including Biograph, correlating its results against benchmarks like VO2 max and brain imaging. Vero is targeting a fall 2027 direct-to-consumer launch, with several thousand people already on its waitlist. Listen to the full conversation on Scott Nelson Live, including Coletta's take on building a founding team, why "capital follows trust" when fundraising, and what he looks for in a board member. Early access Join its waitlist to get priority access to OrganAge(TM) and Vero Compass(TM) as they become more widely available. Early access Join its waitlist to get priority access to OrganAge(TM) and Vero Compass(TM) as they become more widely available.

LCHH Family
Sep 2nd, 2026
LifeCare Home Health & Hospice Family names Dr. Nasser Khan President and Chief Operating Officer.

LifeCare Home Health & Hospice Family names Dr. Nasser Khan President and Chief Operating Officer. September 2, 2026 LifeCare Home Health & Hospice Family has named Dr. Nasser Khan President and Chief Operating Officer, bringing extensive clinical, operational and executive leadership experience to the organization as LifeCare continues to strengthen and grow its family of home health, hospice and personal care companies. In his new role, Dr. Khan will oversee operations across LifeCare's portfolio of companies, working alongside executive and local leadership teams to advance operational excellence, support continued growth and integration, and strengthen the delivery of high-quality care across the communities LifeCare serves. Dr. Khan joins LifeCare with more than two decades of experience spanning healthcare operations, clinical medicine, strategy and organizational leadership. His career has included senior leadership roles across some of the nation's largest and most complex healthcare organizations, with a focus on building high-performing teams, improving operational performance and creating scalable systems that support both growth and quality. Most recently, Dr. Khan served as Chief Operating Officer and Group President of Acadia Healthcare, where he held responsibility for a nationwide behavioral healthcare operation encompassing more than 260 facilities and approximately 25,000 employees. During his tenure, he helped lead significant growth initiatives, operational improvements, health system partnerships and the continued development of leadership teams across the organization. Prior to Acadia Healthcare, Dr. Khan served in senior leadership roles with Shields Health Solutions, DaVita Kidney Care and Biograph. His experience has included healthcare operations, strategic growth, acquisition integration, partnerships and the development of operating platforms across geographically diverse healthcare organizations. Earlier in his career, Dr. Khan was an Engagement Manager with McKinsey & Company, where he advised healthcare organizations on strategy, operational transformation and post-merger integration. What distinguishes Dr. Khan's background is the combination of operational leadership and clinical training he brings to the role. Dr. Khan earned his Doctor of Medicine and Master of Medical Science degrees from Brown University, where he also completed his undergraduate studies in Human Biology. He completed his internal medicine residency at Massachusetts General Hospital and is board certified in Internal Medicine. That clinical foundation has remained an important part of a career increasingly focused on healthcare leadership and the systems that support patients, clinicians and caregivers. "Dr. Khan brings a rare combination of clinical insight, operational experience and demonstrated leadership at scale," said Dean Alverson, Chief Executive Officer of LifeCare Home Health & Hospice Family. "As LifeCare continues to grow, his experience developing teams, strengthening operations and bringing organizations together will be invaluable. Most importantly, he understands that strong operations ultimately serve a larger purpose: helping our teams provide exceptional care to patients and families." Dr. Khan has also remained active within the broader healthcare industry, including service as a member of the Board of Trustees for the National Association for Behavioral Healthcare. Supporting LifeCare's next chapter. Dr. Khan joins LifeCare at an important point in the organization's continued development. LifeCare Home Health & Hospice Family brings together healthcare organizations serving patients and families through home health, hospice, personal care and other home-based services. As the organization continues to expand its reach, LifeCare remains focused on building a connected family of companies while preserving the local relationships, clinical expertise and community presence that define each organization. As President and Chief Operating Officer, Dr. Khan will play a central role in that work. His leadership will include strengthening operational alignment across the organization, supporting LifeCare's continued integration and growth, developing leaders and teams, and helping ensure that the infrastructure behind the organization keeps pace with the needs of the patients, caregivers and communities it serves. For LifeCare, that growth is ultimately about more than scale. It is about creating a stronger healthcare organization capable of supporting high-quality care across a growing network of communities while maintaining the personal connection that is essential to care delivered in the home. "We have an opportunity to continue building an organization that combines strong local care with the resources and capabilities of a larger healthcare family," Alverson said. "Dr. Khan's leadership will help us continue moving that vision forward." LifeCare Home Health & Hospice Family welcomes Dr. Nasser Khan as President and Chief Operating Officer and looks forward to the leadership, perspective and experience he brings to the LifeCare organization.

Longevity.Technology
Aug 20th, 2026
Biograph launches comprehensive women's health program for preventive care.

Biograph launches comprehensive women's health program for preventive care. Biograph has launched a Women's Health Program integrated into its Core and Black tier preventive care model to consolidate female-specific history, personalized hormone testing, comprehensive risk assessment, and tailored nutrition and exercise into longitudinal physician-led care. Research cited in the announcement found U.S. women had a life expectancy of 80 years in 2022, at least two years shorter than women in 13 comparator countries and the highest rate of avoidable mortality among those countries. The program includes a female-specific health history, personalized hormone evaluation interpreted alongside advanced imaging and laboratory testing, individualized lifestyle guidance, and the option for menopausal hormone therapy for clinically eligible members with prescription management and ongoing monitoring. The announcement also cites research that in a cross-sectional study of 4,914 midlife U.S. women, 34% reported moderate to very severe menopause symptoms while about 87% did not seek medical care. Biograph claims 71% of female Black tier members have reversed insulin resistance and 96% of returning female members report measurable progress toward health goals.

Yahoo Finance
Aug 19th, 2026
Biograph launches Women's Health Program to address care gaps across female life stages

Biograph has launched a comprehensive Women's Health Program across its Core and Black tier memberships. The programme addresses gaps in women's healthcare by integrating female-specific health history, personalised hormone testing, comprehensive risk assessments, menopause care, and tailored nutrition and exercise guidance into Biograph's physician-led preventive health model. The initiative responds to persistent healthcare gaps. A 2024 report found US women had a life expectancy of 80 years in 2022, at least two years shorter than women in 13 comparator countries, with the highest rate of avoidable mortality. The programme helps women understand how reproductive history, hormonal transitions, and lifestyle factors affect long-term cardiovascular, metabolic, bone, cognitive, and cancer health. It particularly addresses menopause care gaps, as 87% of women experiencing moderate to severe symptoms do not seek medical care.

Row360
Aug 13th, 2026
Oldest U.S. Olympic oarswoman gets surprise health results and new sporting challenge.

Oldest U.S. Olympic oarswoman gets surprise health results and new sporting challenge. Four-time olympian meghan Musnicki on life after rowing. Words row360. Published 13.08.26. Meghan Musnicki retired after the Paris 2024 Olympics expecting to recalibrate her training. Instead, detailed testing uncovered elevated LDL cholesterol, high lipoprotein(a) and a genetic risk for cardiovascular disease. The results have shaped the 43-year-old American's transition beyond elite rowing. Musnicki, who works for the preventive-health company Biograph in membership development and partnerships, has changed her diet and exercise programme, and begun training for her first marathon. Her rowing résumé made the results unexpected. Musnicki won Olympic gold in the US women's eight at London 2012 and Rio 2016, raced at Tokyo 2020 and, at Paris, became the oldest American woman in Olympic rowing at age 41. The eight finished fifth in the final. Her fitness did not eliminate her inherited cardiovascular risk. Testing changes the plan. Musnicki joined Biograph after an introduction through a mutual connection. The company operates preventive-health clinics in New York and San Francisco, combining diagnostic testing with clinical guidance. "The premise behind all of it is something that obviously really resonated with me given the commitment to living the best life you can live for as long as possible," Musnicki told Sports Business Journal. Testing through Biograph identified high levels of Lp(a), an inherited form of lipoprotein associated with cardiovascular risk. Musnicki had not previously been tested for it. Her father's sudden death from a heart attack at 49, during her freshman year in college, gave the result added weight. "You would think that I would be like a textbook picture of health," she said. "And lo and behold, I have high [Lp(a)], a genetic predisposition to developing cardiovascular disease." The discovery challenged a familiar assumption about elite athletes: exceptional performance can coexist with health risks that routine training data does not detect. Musnicki had spent more than a decade monitoring workload, heart rate, recovery and boat speed, but those measures served Olympic performance rather than a broad assessment of long-term health. "It just makes you pause because no one would look at me and be like, 'Oh, she for sure has high cholesterol,'" she said. "I empower myself with the knowledge of like, okay, this is my reality. And now what choices am I going to make to address and deal with that?" Lifestyle changes before medication. Musnicki chose to try lifestyle interventions before considering a statin. A dietitian and an exercise physiologist helped her develop a plan aimed at reducing her LDL cholesterol and managing her wider risk profile. She reported that her cholesterol fell by 30 points over six months, while her Lp(a) reading dropped by between 25 and 30 points. Lp(a) is largely determined by genetics, so its level and any treatment decisions require individual clinical interpretation. "The value for me wasn't just discovering that I had the issue," Musnicki said. "It was having people that could interpret the information and give me tangible things to do to begin to move the needle. More data isn't always better. It's what you do with it." That distinction mirrors a change she witnessed during her international career. When Musnicki made her first US team in 2010, monitoring centred largely on heart rate and perceived exertion. By her final Olympiad, telemetry could analyse detailed elements of a crew's movement and output. Elite rowing still demanded a narrow objective: make the boat faster within the current selection cycle. Her new programme spreads its attention over a much longer horizon. Strength, sprints and Zone 2. Musnicki continues to train as an endurance athlete, but rowing-specific output no longer governs every session. Heavy lifting now helps her preserve muscle mass and bone density, while Zone 2 cardiovascular work maintains her aerobic base. She has also introduced sprint sessions, jumping, plyometrics and more mobility work. Explosive training has become a priority after years in a sport built around repeated, controlled power. "A lot of it is shifting away from more specific training, again, in thinking of that extraction and thinking more long-term," she said. "As an aging woman, I really focus on making sure I'm doing heavy lifting to preserve my muscle mass and my bone density." Musnicki is also working on her mobility. She said she is trying to shorten the period in the morning when she feels like "the Tin Man", a modest target compared with four Olympic campaigns but one tied directly to daily function. A first marathon after four Olympics. Musnicki is preparing for her first marathon. She has bought a smartwatch to help her train but as yet has not determined the race or a target time. Running offers a new structure after a career spent pursuing selection in the women's eight. Musnicki first tried rowing at St. Lawrence University in 2001 after approaching the athletic department to enquire about basketball. She later transferred to Ithaca College, won NCAA Division III titles in 2004 and 2005, and made the US senior team on her fourth attempt in 2010. She went on to win two Olympic titles and five world titles. The marathon starts from a different position: no seat race, no crew selection and no Olympic cycle, but a fresh endurance problem to solve with a body she now understands differently.